Skip to main content
Back to Trials
NCT07690917Recruiting

A Study of a New PET Scanner in People With Cancer

Memorial Sloan Kettering Cancer Center

Start Date

6/30/2026

Completion Date

6/1/2029

Summary

The researchers are doing this study to test the capabilities of a new total-body PET scanner called the Biograph Vision Quadra. The researchers want to learn whether this scanner can produce better PET/CT images and provide more useful imaging information than standard PET/CT scanners.

Detailed Description

This protocol is a quality improvement protocol intended to explore and capitalize on the advanced performance characteristics of a new total body PET scanner; the Biograph Vision Quadra manufactured by Siemens Healthineers.

Eligibility Criteria

Age Range: 18 years to No maximum

Inclusion Criteria: Eligibility Criteria for objective #1: * Patients with histologically-confirmed non-small cell lung carcinoma (NSCLC) with a single or multiple lung nodules. * Patients who are undergoing a planned PET-CT scan at main campus of MSK. * Patients must be ≥ 18 years old Eligibility Criteria for objective #2: * Patients with disease within the chest, abdomen or pelvis, who could benefit from visualizing the pharmacokinetics of radiotracer uptake within all disease sites simultaneously. * Patients with metastatic prostate or head and neck cancer. * Patients with prostate cancer who are undergoing a 68Ga-PSMA or 18F-FDG scan at the main campus of MSK. * Patients with head and neck cancer who are undergoing a 18F-FDG scan at the main campus of MSK * Patients must be ≥ 18 years old Eligibility Criteria for objective #3: * Patients with histologically-confirmed cancer from all three groups (lung cancer, head and neck cancer, prostate cancer). * Patients who are undergoing an 68Ga-PSMA or 18F-FDG or an \[18F\]-fluormisonidazole PET-CT scan at the main campus of MSK. * Patients willing to return to the MITS clinc for late imaging session between 2 to 6 hours after the PET radiotracer injection. (In current practice, FDG is imaged between 1 and 1.5 hours post injection, and FMISO is imaged between 2.5 and 3 hours post injection) * Patients must be ≥ 18 years old Exclusion Criteria: * Patients who suffer from claustrophobia. * Women who are pregnant or breast-feeding. * Patients \< 18 years of age

Interventions

DIAGNOSTIC_TEST

Biograph Vision Quadra scanner

DIAGNOSTIC_TEST

PET/CT

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Non Small Cell Lung Carcinoma NSCLCHead and Neck CancerProstate Cancer

Locations

Memorial Sloan Kettering Basking Ridge (Consent Only)

Basking Ridge, New Jersey 07920

United States

Memorial Sloan Kettering Monmouth (Consent Only)

Middletown, New Jersey 07748

United States

Memorial Sloan Kettering Bergen (Consent Only )

Montvale, New Jersey 07645

United States

Memorial Sloan Kettering Suffolk-Commack (Consent Only)

Commack, New York 11725

United States

Memorial Sloan Kettering Westchester (Consent Only)

Harrison, New York 10604

United States

Memorial Sloan Kettering Cancer Center

New York, New York 10065

United States

Memorial Sloan Kettering Nassau (Consent Only)

Rockville Centre, New York 11553

United States